Pharming Group Reports Q1 2026 Results: Joenja Revenue Up 34%, Reaffirms Full-Year Guidance Amid Regulatory Progress

summarizeSummary

Pharming Group reported mixed first-quarter 2026 financial results with an 8% revenue decrease, but strong 34% growth in Joenja revenue, improved net loss, positive cash flow, and reaffirmed full-year guidance.

check_boxKey Events

• Q1 2026 Financial Results

  Total revenues decreased 8% year-over-year to US$72.4 million, primarily due to anticipated RUCONEST® declines from inventory drawdowns and non-U.S. market exits.

• Strong Joenja® Revenue Growth

  Joenja® revenue increased 34% to US$14.1 million, driven by robust patient uptake in the U.S. and international markets.

• Improved Profitability & Cash Flow

  Net loss significantly improved to US$5.2 million from US$14.9 million in Q1 2025, and the company generated US$2.0 million in positive net cash flow from operations.

• Full-Year Guidance Reaffirmed

  Pharming Group reaffirmed its 2026 total revenue guidance of US$405 million to US$425 million, representing 8% to 13% growth.

auto_awesomeAnalysis

This filing provides a comprehensive update on Pharming Group's Q1 2026 performance, highlighting a strategic shift and significant pipeline advancements. While total revenues saw an anticipated decline due to RUCONEST® inventory drawdowns and market exits, the robust 34% growth of Joenja® revenue underscores its increasing importance as a key growth driver. The substantial improvement in net loss and positive cash flow from operations demonstrate improved financial discipline. Crucially, the company reaffirmed its full-year revenue guidance, suggesting confidence in its outlook despite the Q1 variability. Significant regulatory milestones, including Joenja® approval in Japan, a positive EU CHMP opinion, and the resubmission of the pediatric sNDA to the FDA, further de-risk and expand the market potential for Joenja®. Investors should monitor the continued uptake of Joenja® and upcoming Phase II readouts for leniolisib in other primary immunodeficiencies.